Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 13/20 | 0.71 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.56 |
| ▸ | CPT2 | P23786 | 1/20 | 0.52 |
| ▸ | CPT1A | P50416 | 1/20 | 0.52 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660323 | 1.00 | PLA2G4A (0.71) | PLA2G4ALTB4RCPT2CPT1ACPT1B | |
| SCHEMBL8536461 | 0.92 | PLA2G4A (0.61) | PLA2G4ALTB4RCPT2CPT1ACPT1B | |
| SCHEMBL3674759 | 0.90 | PLA2G4A (0.59) | PLA2G4ACPT2CPT1ACPT1B | |
| SCHEMBL8951061 | 0.87 | PLA2G4A (0.69) | PLA2G4ALTB4RCYSLTR2CYSLTR1 | |
| SCHEMBL8533898 | 0.87 | CPT2 (0.57) | PLA2G4ALTB4RCPT2CPT1ACPT1B | |
| SCHEMBL8533037 | 0.87 | CPT2 (0.57) | PLA2G4ALTB4RCPT2CPT1ACPT1B | |
| SCHEMBL8951290 | 0.85 | PLA2G4A (0.67) | PLA2G4ALTB4RCYSLTR2CYSLTR1 | |
| SCHEMBL13767658 | 0.85 | PLA2G4A (0.59) | PLA2G4ALTB4RCPT2CPT1ACPT1B | |
| SCHEMBL22768311 | 0.85 | PLA2G4A (0.72) | PLA2G4ALTB4R | |
| SCHEMBL9587112 | 0.83 | PLA2G4A (0.52) | PLA2G4ACYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5391758-A | Leukotriene antagonists | ZENECA, INC. (US) | 1995-02-21 | — | — | US | claimed |
| CN-110183371-B | Preparation process of zafirlukast intermediate | 南京医科大学 | 2022-06-14 | — | — | CN | disclosed |
| WO-2009018280-A2 | SUBSTITUTED INDOLES | AUSPEX PHARAMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20040186300-A1 | Process for the preparation of zafirlukast | FINETECH LABORATORIES LTD. (IL) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186300-A1 | Process for the preparation of zafirlukast | LTC4S, LTB4R, CMA1 | PLA2G4A 466/4885LTB4R 2/4885CPT2 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.